文献速递乳腺癌

低危乳腺浸润性与原位癌保乳术后间质近距离放疗加速部分乳腺照射与全乳照射的晚期副作用与美容效果:随机对照3期试验5年结果

Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-01-14

这项在欧洲7国16中心开展的随机对照3期试验,将1328例40岁及以上、0-IIA期保乳术后女性按1:1分配接受全乳照射50 Gy联合瘤床加量10 Gy或间质近距离放疗加速部分乳腺照射(APBI)。中位随访6.6年时,两组5年晚期毒性谱与美容效果相似,APBI组2-3级晚期皮肤副作用显著更少。

要点

  • 5年任何2级及以上晚期副作用累积发生率全乳照射组27.0% vs APBI组23.3%(p=0.12)。
  • 5年2-3级晚期皮肤毒性累积发生率全乳照射组10.7% vs APBI组6.9%(差值-3.8%,95%CI -7.2至0.4;p=0.020)。
  • 5年患者评价美容效果优良率全乳照射组91% vs APBI组92%(p=0.62)。

核心结论

  • 保乳术后接受间质近距离放疗APBI或常规全乳照射的患者5年毒性谱与美容效果相似,APBI组2-3级晚期皮肤副作用显著更少。
  • 这些发现为低危乳腺癌选择保乳患者常规使用基于间质多导管近距离放疗的APBI提供了进一步临床证据。

研究设计与样本

  • 随机、对照、3期试验,在7个欧洲国家的16个中心开展。
  • 入组40岁及以上、0-IIA期乳腺癌、保乳术后显微镜下切缘阴性且至少2 mm的女性。
  • 按1:1随机分配接受全乳照射50 Gy联合瘤床加量10 Gy或间质近距离放疗APBI,按研究中心、绝经状态和肿瘤类型(浸润性癌 vs 导管原位癌)分层,区组大小10。
  • 2004年4月20日至2009年7月30日共随机分配1328例女性:全乳照射组673例,APBI组655例;按实际接受治疗分析人群1184例(全乳照射组551例,APBI组633例)。
  • 本次报告次要终点晚期副作用与美容效果,分析从保乳手术日期至事件发生日期;试验注册号ClinicalTrials.gov NCT00402519。

主要发现

  • 中位随访6.6年(IQR 5.8-7.6),无患者发生4级毒性。
  • 3级晚期皮肤毒性:APBI组484例中3例(<1%)vs 全乳照射组393例中7例(2%)(p=0.16)。
  • 3级晚期皮下组织毒性:APBI组0例 vs 全乳照射组2例(<1%)(p=0.10)。
  • 5年任何2级及以上晚期副作用累积发生率:全乳照射组27.0%(95%CI 23.0-30.9)vs APBI组23.3%(19.9-26.8)(p=0.12)。
  • 5年2-3级晚期皮肤毒性累积发生率:全乳照射组10.7%(95%CI 8.0-13.4)vs APBI组6.9%(4.8-9.0)(差值-3.8%,95%CI -7.2至0.4;p=0.020)。

关键数值与推荐

  • 全乳照射方案为50 Gy联合瘤床加量10 Gy;APBI采用间质近距离放疗。
  • 5年2-3级晚期皮肤毒性差值-3.8%(95%CI -7.2至0.4;p=0.020),APBI组更低。
  • 5年2-3级晚期皮下组织副作用差值2.4%(95%CI -1.4至6.1;p=0.28),未达统计学显著。
  • 2-3级乳房疼痛差值-3.5%(95%CI -7.1至0.1;p=0.074),未达统计学显著。

临床怎么用

  • 作者认为这些发现为低危乳腺癌选择保乳患者常规使用基于间质多导管近距离放疗的APBI提供了进一步临床证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously confirmed the non-inferiority of accelerated partial breast irradiation (APBI) with interstitial brachytherapy in terms of local control and overall survival compared with whole-breast irradiation for patients with early-stage breast cancer who underwent breast-conserving surgery in a phase 3 randomised trial. Here, we present the 5-year late side-effects and cosmetic results of the trial. METHODS: We did this randomised, controlled, phase 3 trial at 16 centres in seven European countries. Women aged 40 years or older with stage 0-IIA breast cancer who underwent breast-conserving surgery with microscopically clear resection margins of at least 2 mm were randomly assigned 1:1, via an online interface, to receive either whole-breast irradiation of 50 Gy with a tumour-bed boost of 10 Gy or APBI with interstitial brachytherapy. Randomisation was stratified by study centre, menopausal status, and tumour type (invasive carcinoma vs ductal carcinoma in situ), with a block size of ten, according to an automated dynamic algorithm. Patients and investigators were not masked to treatment allocation. The primary endpoint of our initial analysis was ipsilateral local recurrence; here, we report the secondary endpoints of late side-effects and cosmesis. We analysed physician-scored late toxicities and patient-scored and physician-scored cosmetic results from the date of breast-conserving surgery to the date of onset of event. Analysis was done according to treatment received (as-treated population). This trial is registered with ClinicalTrials.gov, number NCT00402519. FINDINGS: Between April 20, 2004, and July 30, 2009, we randomly assigned 1328 women to receive either whole-breast irradiation (n=673) or APBI with interstitial brachytherapy (n=655); 1184 patients comprised the as-treated population (551 in the whole-breast irradiation group and 633 in the APBI group). At a median follow-up of 6·6 years (IQR 5·8-7·6), no patients had any grade 4 toxities, and three (<1%) of 484 patients in the APBI group and seven (2%) of 393 in the whole-breast irradiation group had grade 3 late skin toxicity (p=0·16). No patients in the APBI group and two (<1%) in the whole-breast irradiation group developed grade 3 late subcutaneous tissue toxicity (p=0·10). The cumulative incidence of any late side-effect of grade 2 or worse at 5 years was 27·0% (95% CI 23·0-30·9) in the whole-breast irradiation group versus 23·3% (19·9-26·8) in the APBI group (p=0·12). The cumulative incidence of grade 2-3 late skin toxicity at 5 years was 10·7% (95% CI 8·0-13·4) in the whole-breast irradiation group versus 6·9% (4·8-9·0) in the APBI group (difference -3·8%, 95% CI -7·2 to 0·4; p=0·020). The cumulative risk of grade 2-3 late subcutaneous tissue side-effects at 5 years was 9·7% (95% CI 7·1-12·3) in the whole-breast irradiation group versus 12·0% (9·4-14·7) in the APBI group (difference 2·4%; 95% CI -1·4 to 6·1; p=0·28). The cumulative incidence of grade 2-3 breast pain was 11·9% (95% CI 9·0-14·7) after whole-breast irradiation versus 8·4% (6·1-10·6) after APBI (difference -3·5%; 95% CI -7·1 to 0·1; p=0·074). At 5 years' follow-up, according to the patients' view, 413 (91%) of 454 patients had excellent to good cosmetic results in the whole-breast irradiation group versus 498 (92%) of 541 patients in the APBI group (p=0·62); when judged by the physicians, 408 (90%) of 454 patients and 503 (93%) of 542 patients, respectively, had excellent to good cosmetic results (p=0·12). No treatment-related deaths occurred, but six (15%) of 41 patients (three in each group) died from breast cancer, and 35 (85%) deaths (21 in the whole-breast irradiation group and 14 in the APBI group) were unrelated. INTERPRETATION: 5-year toxicity profiles and cosmetic results were similar in patients treated with breast-conserving surgery followed by either APBI with interstitial brachytherapy or conventional whole-breast irradiation, with significantly fewer grade 2-3 late skin side-effects after APBI with interstitial brachytherapy. These findings provide further clinical evidence for the routine use of interstitial multicatheter brachytherapy-based APBI in the treatment of patients with low-risk breast cancer who opt for breast conservation. FUNDING: German Cancer Aid.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Polgár C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017. PMID: 28094198. doi:10.1016/S1470-2045(17)30011-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。